Bioterrorism legislation
This article was originally published in The Gray Sheet
Executive Summary
Senate bill (1764) sponsored by Sen. Lieberman (D-Conn.) would give net operating loss refunds for biotech companies researching diagnostic devices for biological or chemical agents used in terrorist attacks. S 1764 is expected to merge with the Bioweapons Preparedness Act of 2001 (S 1715), sponsored by Sens. Frist (R-Tenn.) and Kennedy (D-Mass.), which grants the Office of Homeland Security the authority to set research priorities that would help fight bioterrorism. Companies working on named priorities would be eligible for incentives including a zero capital gains tax rate on any gains realized on the stock. The bill would apply to firms with less than $750,000 in paid-in capital...
You may also be interested in...
Lieberman Counter-Terrorism Bill Brings Diagnostic Incentives Into The Mix
Sen. Joe Lieberman's (D-Conn.) bill to provide incentives for development of bioterrorism countermeasures is being revised to increase attention on diagnostics
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.